Quantcast

Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments

November 5, 2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ — Sermo (http://www.sermo.com), the world’s largest online community for physicians, today announced a free Sermo Report titled, “Treatment Options for Gout“. The report gathered feedback from physicians to better understand how they currently treat gout and if they would consider using new treatments.

While many physicians who participated felt that current gout treatments effectively manage acute and suppressed gout flares, 63% confirmed they would utilize new gout medications as they become available. Physicians also listed many different patient types that would benefit from new gout treatments, including recurrent gouty arthritis, tophaceous gout and those resistant to current treatments.

This free Sermo Report polled 114 physicians across multiple specialties, of which 89% see an average of 19 gout patients per month. Many of the respondents also participated in an online discussion regarding various treatment strategies and how they plan to use newly available therapies.

The full reports includes:

  • Key Findings
  • Physician Demographics
  • Discussion Highlights
  • Quantitative and Qualitative Post Analysis

Companies that are in the process of developing or have approved gout treatments include Takeda Pharmaceuticals, Savient Pharmaceuticals, Cardiome Pharma Corp., Regeneron Pharmaceuticals, Ardea Biosciences and Novartis.

To download full results of this free report, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, trends, and other topics of interest. Data for Sermo Reports is
gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic. All physicians on Sermo are verified and credentialed.

About Sermo

Sermo is the largest online physician community, where over 117,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo’s social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit www.sermo.com/client.

SOURCE Sermo


Source: newswire



comments powered by Disqus